skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis

Bonga, Krishna Nikhila ; Mishra, Archana ; Maiti, Rituparna ; Padhy, Biswa Mohan ; Meher, Bikash Ranjan ; Srinivasan, Anand

Obstetrics and gynecology (New York. 1953), 2024-03, Vol.143 (3), p.393-402 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
  • Título:
    Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis
  • Autor: Bonga, Krishna Nikhila ; Mishra, Archana ; Maiti, Rituparna ; Padhy, Biswa Mohan ; Meher, Bikash Ranjan ; Srinivasan, Anand
  • Assuntos: Female ; Genital Diseases, Female ; Heterocyclic Compounds, 2-Ring - therapeutic use ; Hot Flashes - drug therapy ; Humans ; Menopause ; Quality of Life ; Thiadiazoles
  • É parte de: Obstetrics and gynecology (New York. 1953), 2024-03, Vol.143 (3), p.393-402
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-1
    content type line 23
  • Descrição: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause. PubMed/MEDLINE, ClinicalTrials.gov , EMBASE, Cochrane Database, Scopus, and WHO International Clinical Trials Registry Platform were searched through June 2023 for publications and randomized controlled trials on fezolinetant compared with placebo in menopausal women who experienced moderate-to-severe VMS. Our literature search identified 330 articles, of which five studies with six reports were included in our meta-analysis per our eligibility criteria. The risk of bias was evaluated using Cochrane's RoB 2 (Risk of Bias version 2) tool, quality of evidence was graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, and outcome measures data for effect size were pooled in random-effects model and rated. A total of 2,168 participants from five randomized clinical trials (six reports) were included. Fezolinetant significantly lowered VMS frequency, with pooled mean difference of 2.62 (95% CI, 1.84-3.41). The pooled mean difference for fezolinetant compared with placebo for the MENQOL (Menopause-Specific Quality of Life) measure was -0.60 (95% CI, -0.92 to -0.28), and the mean percentage improvement in VMS frequency was 22.51% (95% CI, 15.35-29.67). Fezolinetant was associated with improvement in sleep quality when compared with placebo. Fezolinetant is effective in lowering moderate-to-severe VMS frequency and sleep disturbances in postmenopausal women. PROSPERO, CRD42023427616.
  • Editor: United States
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.